Diadema Partners’s Definium Therapeutics DFTX Stock Holding History

Diadema Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-105,891	Closed	-$1.25M	–	170
2025 Q3	$1.25M	Sell	105,891 -52,645	-33%	-$491K	0.32%	79
2025 Q2	$1.03M	Buy	+158,536	New	+$1.04M	0.31%	61
2025 Q1	–	Sell	-4,710	Closed	-$32.8K	–	140
2024 Q4	$32.8K	Buy	+4,710	New	+$32.4K	0.01%	101

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Diadema Partners's DFTX Position: Q4 2025 in Review

Diadema Partners sold out of Definium Therapeutics (DFTX) in Q4 2025, closing a stake of 105,891 shares — an estimated $1.25M sold.

Diadema Partners first reported a position in DFTX in Q4 2024 and held it in 3 quarters. The position peaked at $1.25M in Q3 2025. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

Diadema Partners reported no remaining Definium Therapeutics position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 105,891 Definium Therapeutics shares in Q4 2025, an estimated $1.25M.
Diadema Partners first reported a position in Definium Therapeutics in Q4 2024 and held it in 3 quarters.
Diadema Partners's Definium Therapeutics position peaked at $1.25M in Q3 2025.
208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.